Here are four key points:
1. Some major companies’ stocks have soared following the news of a Republican win, with Roche and Novartis, both based in Switzerland, shares both jumping 4 percent.
2. British-based GlaxoSmithKline shares are trading 1.8 percent higher.
3. Business Insider reports this pricing surge following the election results is due to the fact that President-elect Donald Trump will likely not pass very controlling drug pricing legislation.
4. Chicago-based Deutsche Bank analysts had said, “European healthcare would likely outperform under a Trump win, given it has moved inversely to the probability of a Clinton victory over the past couple of months and has historically done well in periods of rising macro uncertainty and dollar strength.”
More healthcare news:
What will happen to value-based care under the Donald Trump presidency?
10 key steps to immediately improve ASC finances
Donald Trump’s alternative to ACA adds $41B+ to the deficit: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
